Technical Analysis for ARGX - argenx SE

Grade Last Price % Change Price Change
grade B 125.54 -4.89% -6.46
ARGX closed down 4.89 percent on Friday, March 22, 2019, on 1.22 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ARGX trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 New Downtrend Bearish 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 Wide Range Bar Range Expansion 0.00%
Mar 22 Multiple of Ten Bearish Other 0.00%
Mar 21 1,2,3 Pullback Bullish Bullish Swing Setup -4.89%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.89%
Mar 21 Bollinger Band Squeeze Range Contraction -4.89%
Mar 21 Inside Day Range Contraction -4.89%

Older signals for ARGX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Biopharmaceutical Cancer Solid Tumors Immunotherapy Autoimmune Diseases Rheumatoid Arthritis Acute Myeloid Leukemia Myelodysplastic Syndrome Dyslipidemia Hematological Cancers Treatment Of Autoimmune Diseases Myasthenia Gravis Janus Kinase Inhibitor Treatment Of Hematological Cancers Tolerx
Is ARGX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 135.58
52 Week Low 63.81
Average Volume 178,564
200-Day Moving Average 96.9372
50-Day Moving Average 118.1196
20-Day Moving Average 129.56
10-Day Moving Average 129.26
Average True Range 3.7045
ADX 28.8
+DI 28.405
-DI 32.3913
Chandelier Exit (Long, 3 ATRs ) 124.4665
Chandelier Exit (Short, 3 ATRs ) 131.0735
Upper Bollinger Band 137.1303
Lower Bollinger Band 121.9897
Percent B (%b) 0.23
BandWidth 11.686169
MACD Line 3.1489
MACD Signal Line 3.8803
MACD Histogram -0.7314
Fundamentals Value
Market Cap 3.37 Billion
Num Shares 26.9 Million
EPS -1.27
Price-to-Earnings (P/E) Ratio -98.85
Price-to-Sales 15.41
Price-to-Book 3.49
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 138.89
Resistance 3 (R3) 139.49 135.65 136.67
Resistance 2 (R2) 135.65 132.25 135.35 135.92
Resistance 1 (R1) 130.59 130.15 128.67 129.99 135.18
Pivot Point 126.75 126.75 125.79 126.45 126.75
Support 1 (S1) 121.69 123.35 119.77 121.09 115.90
Support 2 (S2) 117.85 121.25 117.55 115.16
Support 3 (S3) 112.79 117.85 114.42
Support 4 (S4) 112.19